Abstract 16q22.1-linked autosomal dominant cerebellar ataxia (16q-ADCA) is a recently defined subtype of ADCA identified by a disease-specific C/T substitution in the 5′ untranslated region of the puratrophin-1 gene. In Nagano, the central mountainous district of the main island of Japan, 16q-ADCA and spinocerebellar ataxia type 6 (SCA6) are the most and second most prevalent subtypes of ADCA, respectively. Both subtypes are classified into Harding's ADCA III, but little attention has been given to the differences in the severity and progression rate of cerebellar ataxia between 16q-ADCA and SCA6. We investigated the clinical severity and progression rate of cerebellar ataxia of 16q-ADCA patients using international cooperative ataxia rating scale and scale for the assessment and rating of ataxia and compared them with those of SCA6 patients. The age at onset was much higher in 16q-ADCA patients (60.1±9.8 years, n= 66) than in SCA6 patients (41.1±8.7 years, n=35). Clinical features of 16q-ADCA were basically consistent with pure cerebellar ataxia, as well as in SCA6, but gaze-evoked nystagmus was observed less frequently in 16q-ADCA patients than in SCA6 patients. When compared at almost the same disease duration after onset, the severity of cerebellar ataxia was a little higher, and the progression rate seemed more rapid in 16q-ADCA patients than in SCA6 patients, but the differences were not significant.
Introduction
Autosomal dominant cerebellar ataxia (ADCA) is a genetically and clinically heterogeneous group of diseases characterized by a slowly progressive gait and truncal unsteadiness and dysarthria and often associated with poor coordination of hands [1, 2] . The incidence of the subtypes of ADCA is quite variable in countries [2] . Even in Japan, the incidence of the subtypes varies in different areas [3] [4] [5] . In general, SCA3/Machado-Joseph disease or spinocerebellar ataxia type 6 (SCA6) are the most or second most predominant subtypes, and dentatorubral-pallidoluysian atrophy is the third most prevalent subtype in Japan [2] [3] [4] [5] .
Recently, a new subtype called 16q22.1-linked ADCA (16q-ADCA) has become recognized [6] [7] [8] [9] . A singlenucleotide substitution (−16C>T) in the 5′ untranslated region of the gene encoding puratrophin-1 has been shown to be a disease-specific marker for 16q-ADCA [10, 11] . According to the availability of a diagnostic marker for 16q-ADCA, the prevalence of this subtype has been estimated as 8-17% in ADCA families in Japan [12] [13] [14] [15] [16] . But, so far, this specific substitution has been found exclusively in the Japanese population [17] . Thus, it is still unclear whether 16q-ADCA exists in countries other than Japan.
In our previous study, we have shown that 16q-ADCA is the most predominant subtype of ADCA in Nagano, which is located in the central, mountainous district of the main island of Japan [18, 19] . To date, we have analyzed 143 ADCA families from Nagano and diagnosed 61 families (42.7%) with 16q-ADCA and 29 (20.3%) with SCA6. Thus, the frequency of 16q-ADCA in Nagano is much higher than in the other areas of Japan [12] [13] [14] [15] [16] . In particular, the frequency of 16q-ADCA is extremely high in the restricted areas of Nagano, 25/31 (80.6%) in the southwest area (Ina-Kiso area) and 17/26 (65.4%) in the east area (Saku area), reflecting the accumulation of 16q-ADCA families in these areas.
Clinically, both 16q-ADCA and SCA6 show pure cerebellar ataxia of late onset [10] [11] [12] [13] [14] [15] 19] and are classified into ADCA III according to Harding's criteria [20] , but little attention has been given to the differences in the severity and progression rate of cerebellar ataxia between 16q-ADCA and SCA6 patients. It is quite difficult to differentiate between 16q-ADCA and SCA6 without genetic testing. In fact, most families with 16q-ADCA in the Nagano area had been considered as having SCA6 before genetic testing.
In consideration of the high frequency of 16q-ADCA in Nagano and the clinical similarities of both subtypes, we have investigated the clinical features of 16q-ADCA in the endemic Nagano area in more detail. The main purpose of this study was to clarify if the clinical severity and progression rate of cerebellar ataxia were different between 16q-ADCA and SCA6. We also tried to verify whether or not the clinical features of 16q-ADCA patients in the endemic Nagano area were different from those in nonendemic areas in Japan.
Materials and Methods

Subjects
To date, we have genetically confirmed 89 patients with 16q-ADCA from 61 families and 42 patients with SCA6 from 29 families in Nagano. From these families, we have recruited 66 patients with 16q-ADCA and 35 patients with SCA6 in this study. Some of the affected individuals with 16q-ADCA or SCA6, who were dead, institutionalized, or no longer lived in Nagano, could not be examined by us, but their medical records were available. This research protocol was approved independently by the Ethical Committee of Shinshu University School of Medicine and by the Committee for Ethical Issues at Yokohama City University Graduate School of Medicine.
Clinical Evaluations
Detailed medical interviews and routine neurological examinations were done by expert neurologists. Age at onset was determined on the basis of the information provided by the patients or their close relatives. International cooperative ataxia rating scale (ICARS) [21] and scale for the assessment and rating of ataxia (SARA) [22] were used for the assessment of cerebellar ataxia. The patients with 16q-ADCA (n=52) or with SCA6 (n=25) were evaluated with ICARS and SARA simultaneously by either of the first two authors. Hearing impairment was judged as positive when the patient felt difficulty in daily conversation. Audiograms were performed only for a minority of the patients.
Statistics
Statistical analysis was performed using the Student's t test (Microsoft Office Excel 2003). Regression analysis for ICARS and SARA data was done with Microsoft Office Excel 2003. The level of significance was set at p<0.01.
Results
Neurological findings are summarized in Table 1 . The age at onset was 60.1±9.8 and 41. 1±8.7 in 16q-ADCA (n=66) and SCA6 (n=35), respectively. All the patients with 16q-ADCA showed gait unsteadiness with or without dysarthria as initial symptoms. Neither pyramidal nor extrapyramidal tract signs were common for 16q-ADCA, as well as for SCA6. Deep tendon reflexes were variable, but the Babinski reflex was generally negative in 16q-ADCA. Cognitive impairment was found in four patients (6.1%) with 16q-ADCA. Hearing impairment was noted in ten patients (15.2%) with 16q-ADCA. All four patients with cognitive impairment were over 80 years (80-86 years, mean 81.8 years) and negative for other evident causes of dementia on brain magnetic resonance imaging (MRI). Ten patients with hearing impairment were aged between 65 and 85 years (mean 78.9 years), and three of them had a history of repetitive otitis media. Three patients had both cognitive and hearing impairment. Mild or moderate hand tremor or head titubation was seen in some patients with 16q-ADCA, but only one patient underwent deep brain stimulation for disabling hand tremor.
The scores of ICARS and SARA are shown in Table 2 , and the correlation between ICARS or SARA and age at examination or duration of illness is shown in Fig. 1 . The ICARS and SARA scores were well correlated in each patient. Both the total scores of ICARS and SARA were a little higher in 16q-ADCA patients than in SCA6 patients (Table 2 ), but the difference was not significant. Contrary to the other three subscores in ICARS, only the oculomotor disorder subscore was lower in 16q-ADCA patients (1.8± 1.4) than in SCA6 patients (3.2±1.1; Table 2 ). This is mainly because gaze-evoked nystagmus was more evident in SCA6 patients than in 16q-ADCA patients. The patients with persistent gaze-evoked nystagmus (gaze-evoked nystagmus score 2 or 3 on ICARS [21] ) were observed more frequently in SCA6 (17/25, 68.0%) than in 16q-ADCA (6/52, 11.5%). Cerebellar ataxia was slowly progressive in both 16q-ADCA and SCA6 patients, and the ICARS and SARA scores seemed to increase more rapidly in 16q-ADCA patients than in SCA6 patients (Fig. 1 ), but the difference was not significant.
Discussion
16q-ADCA is the most prevalent subtype of ADCA (42.7% in ADCA) in the Nagano area, where two main foci are identified in the southwest area (Ina-Kiso area) and east area (Saku area) of Nagano. In these areas, the incidence of spinocerebellar degeneration is higher than in the other areas of Nagano, mainly because of an accumulation of 16q-ADCA families [19] . Having two large foci of 16q-ADCA, Nagano is considered to be an endemic area for 16q-ADCA in Japan.
In the present study, we first investigated the severity and progression rate of cerebellar ataxia in a large population of 16q-ADCA patients, using ICARS and SARA, and compared them with those in SCA6 patients. Both these scales have been shown to exhibit high interrater reliability [22, 23] and are widely used for evaluation for ataxic patients. Both the total scores of ICARS and SARA were a little higher in 16q-ADCA patients than in SCA6 patients at almost the same disease duration after onset. The rate of disease progression seemed more rapid in 16q-ADCA patients than in SCA6 patients. But the differences in the severity and progression rate were not significant. The major concern for interpreting the data is that the ages of the patients in both groups were considerably different, even though the mean disease duration was not different between the two groups. In particular, the mean age at onset of our SCA6 patients was younger than reported previously [24] [25] [26] [27] , although the reason for this was unknown. As a result, the mean age at examination in 16q-ADCA patients (72.5±8.5 years, n=52) was about 15 years older than in SCA6 patients (57.2±11.0 years, n=25). Therefore, we should keep in mind that the effect of aging-related factors (e.g., degenerative arthropathy, disuse atrophy of lower extremities) might modify the clinical severity and progression rate more seriously for 16q-ADCA patients than for SCA6 patients.
Patients with 16q-ADCA in the endemic Nagano area showed pure cerebellar ataxia with late onset, which is basically compatible with those in nonendemic areas in Japan (Table 3 ) [12] [13] [14] [15] . The mean age at onset in our patients was almost the same as that in patients in nonendemic areas. This is in contrast to the case for transthyretin Met30-associated familial amyloid polyneuropathy (FAP TTR Met30). Nagano has been known to be one of worldwide foci for FAP TTR Met30. In FAP TTR Met30, patients from the endemic foci show features distinct from those of patients from nonendemic areas in Japan [28, 29] . For example, the age at onset is generally younger in the former patients than in the latter patients [28, 29] . A founder effect may be much more profound or diseasemodifying factors other than the causative gene mutation may be less influential in 16q-ADCA than in TTR FAP Met30.
As reported previously for 16q-ADCA patients in nonendemic areas [12] [13] [14] [15] , extracerebellar symptoms and signs were rare in our patients in the endemic Nagano area. In our study, cognitive and hearing impairment were observed in four (6.1%) and ten (15.2%) patients, respectively. The mean ages of the patients with cognitive or hearing impairment were almost 80 years or over. This was supportive of the observation of Nozaki et al. [14] that extracerebellar features were observed more frequently in elderly patients aged over 65 years. Hayashi et al. [16] reported that the frequency of dementia, pyramidal, extrapyramidal signs, and leukoaraiosis on brain MRI was considerable in their 12 patients with 16q-ADCA. This observation was quite unique in terms of the high frequency of extracerebellar features and leukoaraiosis, when compared with reports from other districts of Japan including ours [12] [13] [14] [15] 19] . In our series, leukoaraiosis was not seen in brain MRI, even in the four patients with cognitive impairment. The extracerebellar features and leukoaraiosis described by Hayashi et al. [16] could be due to phenotypic variation of 16q-ADCA or a coincidental effect of other factors peculiar to their 16q-ADCA patients. Further clinical and neuropathological investigations are required to clarify the disease characteristics of 16q-ADCA.
Gaze-evoked nystagmus is one of the cardinal features of SCA6 [24] [25] [26] [27] . This was again confirmed in our study. On the other hand, gaze-evoked nystagmus was less frequently observed in 16q-ADCA patients, reflecting that the oculomotor disorders subscores were significantly lower in 16q-ADCA patients than in SCA6 patients. The pathogenesis of gaze-evoked nystagmus has been discussed in association with the lesions pathologically involved [30] . Purkinje cell degeneration is the most prominent pathological finding in both SCA6 and 16q-ADCA [30, 31] . The difference in the frequency in gaze-evoked nystagmus between SCA6 and 16q-ADCA may be due to the difference of the degree and distribution of affected lesions between both diseases.
In conclusion, there was no clear difference in clinical features in 16q-ADCA patients from the endemic Nagano area and nonendemic areas in Japan. The mean age at onset in 16q-ADCA patients was significantly higher than that in SCA6 patients. The total scores of ICARS and SARA at almost the same disease duration were higher, but the oculomotor disorder subscore on ICARS was lower in 16q-ADCA patients than in SCA6 patients. The progression rate of cerebellar ataxia judged by ICARS and SARA might be more rapid in 16q-ADCA patients than in SCA6 patients, but it is possible that other physical factors related to aging have a greater influence upon these scores in 16q-ADCA patients than in SCA6 patients.
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